Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ: CRBP · IEX Real-Time Price · USD
0.258
+0.006 (2.42%)
At close: Jul 1, 2022 4:00 PM
0.256
-0.002 (-0.736%)
After-hours: Jul 1, 2022 7:56 PM EDT
2.42%
Market Cap 32.35M
Revenue (ttm) 233,881
Net Income (ttm) -39.01M
Shares Out 125.26M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 207,227
Open 0.277
Previous Close 0.252
Day's Range 0.256 - 0.277
52-Week Range 0.208 - 1.790
Beta 2.03
Analysts Buy
Price Target 2.02 (+682.0%)
Earnings Date Aug 11, 2022

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks t... [Read more...]

Industry Biotechnology
Founded 2009
CEO Yuval Cohen
Employees 41
Stock Exchange NASDAQ
Ticker Symbol CRBP
Full Company Profile

Financial Performance

In 2021, CRBP's revenue was $881,705, a decrease of -77.61% compared to the previous year's $3.94 million. Losses were -$45.64 million, -58.98% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CRBP stock is "Buy." The 12-month stock price forecast is 2.02, which is an increase of 682.04% from the latest price.

Price Target
$2.02
(682.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunothe...

CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGF b in the local tumor microenvironment Additional non-clinical data demonstrates co...

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023 Ex...

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

NORWOOD, Mass. , April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB...

Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote

Marijuana penny stocks to watch right now. The post Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: GNLNHEXOSNDL

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.

Other symbols: BKEIQTH

Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORWOOD, Mass., March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that  Yuval Cohen, Ph.D.

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported finan...

After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree...

Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning...

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D.

Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported finan...

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D.

Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Corbus Pharmaceuticals Q2 Earnings

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15)...

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported fina...

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other symbols: ABUSDBGIJFUNBYNXE

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomy...

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflamm...

3 Biotech Stocks With Big Catalysts in June

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

Other symbols: GMTXNTLA

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

This Biotech Penny Stock Is Better Than Dogecoin

You might want to avoid buying it, though.

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs),...

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other symbols: EYESTYME